消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

中国临床肿瘤学会 中国临床肿瘤学会

治疗胃癌诊断

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

中文标题：

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

英文标题：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

发布机构：

中国临床肿瘤学会

发布日期：

简要介绍：

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a97061c00212583c, title=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）, enTitle=The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021, guiderFrom=中国临床肿瘤学会, authorId=0, author=, summary=本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。, cover=https://img.medsci.cn/202175/1625470678288_5433779.jpeg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。</span></p>, tagList=[TagDto(tagId=65, tagName=治疗), TagDto(tagId=438, tagName=胃癌), TagDto(tagId=757, tagName=诊断)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=438, articleKeyword=胃癌, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15819, appHits=942, showAppHits=0, pcHits=2478, showPcHits=14873, likes=4, shares=74, comments=40, approvalStatus=1, publishedTime=Mon Jul 05 15:40:21 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=5433779, editor=Oranhyg是正经人, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=Oranhyg是正经人, createdTime=Mon Jul 05 15:38:09 CST 2021, updatedBy=5433779, updatedName=Oranhyg是正经人, updatedTime=Sat Jan 06 17:44:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)])
2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf
下载请点击：
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-15 吴卓远108

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-04 ms2000000908561621

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-23 ms6000000590698351

    有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 147c0641m47暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 嗜酸性筋膜炎的诊断标准，严重性分级和治疗指南

国外皮肤性病相关专家小组（统称） · 2017-12-13

2017 ASA立场声明：成人失眠症的心理/行为治疗

澳大拉西亚睡眠协会(ASA,Australasian Sleep Association) · 2017-06-20

2017 NAMS立场声明：激素治疗

北美绝经学会(NAMS,The North American Menopause Society) · 2017-06-24

解读2015年美国风湿病学会强直性脊柱炎和放射学阴性中轴型脊柱关节炎新的治疗推荐

暂未更新 · 2016-07-30

中国成人艰难梭菌感染诊断和治疗专家共识

暂未更新 · 2017-06-20

2016年中国超重/肥胖医学营养治疗专家共识解读

暂未更新 · 2017-05-30

拓展阅读

北肿沈琳团队研究登《柳叶刀》：胃癌进展或死亡风险降低63%！CAR-T治疗实体瘤新突破

该研究是“首个CAR-T疗法治疗实体瘤的随机对照试验”。基于本次研究结果，satri-cel有望成为CLDN18.2阳性晚期胃癌/食管胃结合部腺癌患者的三线治疗新选择。

European Radiology：基于计算机断层成像的定量参数结合细胞外体积分数预测胃癌淋巴结转移

细胞外体积分数（ECV%）是血管外细胞外体积分数和血管内空间分数的总和。相关研究证实，基于影像的 ECV% 与基于组织活检的细胞外间质量一致，因此，基于影像的 ECV% 可定量表征病变的细胞外间质量。

胃癌诊疗 “新势力”：前沿资讯 + 实用公式，一文解锁临床进阶密码

有热门资讯，追踪胃癌研究最新成果；有医学知识深度剖析，梳理疾病要点；更有实用公式解读，成为你临床决策的得力助手。快来社群查看，一起探讨学习，为胃癌诊疗注入新能量！

NEJM：总生存期达14.7个月！这类胃癌或迎来新二线治疗策略

DESTINY-Gastric04 研究显示，德曲妥珠单抗用于 HER2 阳性转移性胃癌二线治疗，中位 OS 达 14.7 个月，较标准方案延长 3.3 个月，安全性可控，为患者提供新策略。

沈琳教授团队研究荣登国际期刊 | 全球首个CAR-T细胞疗法治疗实体瘤研究结果发布！

北京大学肿瘤医院沈琳团队开展全球首个 CLDN18.2 CAR-T 胃癌随机对照 2 期试验，显示 satri-cel 较传统治疗显著延长晚期胃癌患者 PFS，安全性可控，为三线治疗提供新选择。

破解耐药难题：彭智教授谈胃癌免疫治疗的前沿研究与临床启示

【医悦汇】特邀北京大学肿瘤医院彭智教授做客对话大咖，深入探讨了SHR-1701的双靶点机制、免疫治疗在胃癌围手术期的应用前景以及耐药机制的研究进展。